GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ER-306323 | ER306323 | Orserdu® | RAD-1901 | RAD1901
                                 
                                                         
                            
                            
                            
                                 
                                
                                elacestrant is an approved drug (FDA & EMA (2023)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Elacestrant is an orally bioactive, selective, non-steroidal dual estrogen receptor degrader (SERD)/selective estrogen receptor modulator (SERM; with antagonist action) [6]. It was developed primarily for antineoplastic potential (via its SERD action at high concentrations) [3]. It has also demonstrated potential to treat the vasomotor symptoms of the menopause with estrogen-like effects detected at low concentrations (SERM activity), but the pharmacology in this setting is very complex [4]. Elacestrant crosses the blood-brain barrier, so is predicted to provide efficacy against breast cancer metastases in the brain.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| Elacestrant inhibits estrogen-induced activation of ERα-mediated gene transcription in vitro and in vivo (SERM action), and downregulates ESR1 expression in MCF-7 cells (SERD action) [6] |